Randomised phase 3 trial: tegoprazan, a novel potassium‐competitive acid blocker, vs. esomeprazole in patients with erosive oesophagitis

BACKGROUND: Tegoprazan is a novel potassium‐competitive acid blocker that has a fast onset of action and can control gastric pH for a prolonged period, which could offer clinical benefit in acid‐related disorders. AIM: To confirm the non‐inferiority of tegoprazan to esomeprazole in patients with ero...

Descripción completa

Detalles Bibliográficos
Autores principales: Lee, Kwang Jae, Son, Byoung Kwan, Kim, Gwang Ha, Jung, Hye‐Kyung, Jung, Hwoon‐Yong, Chung, Il‐Kwun, Sung, In‐Kyung, Kim, Jin Il, Kim, Jong Hyeok, Lee, Joon Seong, Kwon, Joong Goo, Park, Jung Ho, Huh, Kyu Chan, Park, Kyung Sik, Park, Moo‐In, Kim, Nayoung, Lee, Oh Young, Jee, Sam Ryong, Lee, Sang Kil, Youn, Sei Jin, Kim, Sung Kook, Lee, Soo Teik, Hong, Su Jin, Choi, Suck Chei, Kim, Tae Nyeun, Youn, Young Hoon, Park, Hyo Ju, Kang, Min Ja, Park, Chi Hye, Kim, Bong Tae, Youn, Sangjun, Song, Geun Seog, Rhee, Poong‐Lyul
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2019
Materias:
Randomised Clinical Trial
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6594096/
https://www.ncbi.nlm.nih.gov/pubmed/30843245
http://dx.doi.org/10.1111/apt.15185

Ejemplares similares

Ejemplares similares